The Phase III raise encompassed the costs for a go-it-alone reformulation strategy, with Bell Potter suggesting in a Q&A with IXC that they saved $5-6M in going with Peptron for their reformulation supply/manufacturing, alongside 12 months in time.
I would wager that the above, alongside the existing Phase III contingency baked into the last $26M raise will be enough for early work streams for Phase II work (and with Biotech timelines, a phase II trial wont be ready until 2025 when a Phase III read out is to occur anyway, where CR will be far cheaper than where we are today).
- Forums
- ASX - By Stock
- IXC
- Ann: Publication of Invex IIH Phase II Pressure Trial Results
Ann: Publication of Invex IIH Phase II Pressure Trial Results, page-7
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.062 |
1 | 15500 | 0.061 |
1 | 150000 | 0.060 |
1 | 100000 | 0.052 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 10000 | 1 |
0.069 | 16500 | 1 |
0.070 | 40000 | 1 |
0.076 | 888 | 1 |
0.083 | 4000 | 1 |
Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable